Introduction
Breast cancer is the most common cancer among women with 1.6 million new cases and approximately half million deaths per year. [1] One-fifth of these cancers are Her2-positive which follows a more aggressive course. [2] Over the last 15 years, we have made significant progress in treating these patients with Her2-targeted therapy. [3] Her2 assessment can be done at DNA, RNA, and protein levels. The College of American Pathologists/American Society of Clinical Oncology (CAP/ ASCO) recommends immunohistochemistry (IHC) to detect Her2 positivity at protein level, combined, in equivocal cases by in situ hybridization (ISH) assay with chromogenic or fluorescent probes (FISH, gold standard conventional pathway) for assessing Her2 at DNA level. [2, 4] However, both tests are criticized for being cumbersome, expensive, time-consuming, and difficult to standardize. [5, 6] Concerns have also been raised about reproducibility of Her2 protein assessment by IHC in formalin-fixed tissues. [7] In contrast, polymerase chain reaction (PCR)-based methodologies do not have the issue of interobserver variation as they involve quantitative measurements to detect Her2 positivity at DNA and RNA level and thus can be easily standardized and automated. [8] [9] [10] [11] [12] Most of the previous experiences with PCR-based tests utilized real-time PCR (RTPCR), and results of concordance with FISH have been mixed. [13, 14] However, an issue with PCR-based testing that needs to be understood is that while FISH categorizes almost all patients as "positive" or "negative," PCR-based tests return a continuous score. Thus, we need to define cutoffs while comparing against a gold standard, quantitative variability, and does not require calibration curves before actual samples are run as opposed to RTPCR. [20, 21] This is because DDPCR is directly dependent upon both the number of absolute replicate measurements and the template concentration while RTPCR needs known calibrators. Thus, using a protocol similar to our previous study, we aimed to assess if DDPCR could offer a viable alternative for improvisation over conventional IHC and FISH testing for ascertaining Her2 status of breast cancer.
Materials and Methods
Ours is a tertiary care regional cancer center based in northern India. Annually more than 300 primary unilateral treatment-naive breast cancer cases are treated by our medical oncology service. [22] Our conventional protocol for breast cancer diagnosis and Her2 expression testing is described elsewhere and is in agreement with 2013 CAP/ASCO guidelines. [19] Since this study was aimed to ascertain characteristics of DDPCR as a diagnostic test, after the Institutional Ethics Committee approval, we decided to perform IHC, FISH, and DDPCR on all consecutive primary treatment-naive cases for an arbitrary duration of 2 months from June to August 2017.
Tissue processing protocol
The immunostaining procedures were performed using formalin-fixed paraffin-embedded (FFPE) tissue sections. RTU antibodies were used for Her2 (rabbit monoclonal antibody 4B5) on Ventana, Arizona, USA, automated IHC slide stainer BenchMark XT. FISH reaction was performed with PathVysion Her2 DNA Probe Kit (Abbott Molecular, Illinois, USA) according to the manufacturer's instructions. Analysis of Her2/CEP17 signals was done using Leica DM 6000B, Germany, and results were scored as "positive" (Her2:CEP-17 ratio >2 with an average Her2 copy number >4 signals/cell or Her2:CEP 17 >2 with an average Her2 copy number <4 signals/cell or Her2:CEP17 ratio <2 with an average Her2 copy number >6 signals/cell), "negative" (Her2:CEP17 ratio <2 an average Her2 copy number <4 signals/cell), or "equivocal" for Her2 amplification (Her: CEP17 ratio <2 with an average Her2 copy number >4 and <6 signal/cell).
For RNA assessment, FFPE tissues from breast tumor samples with more than 30% tumor tissue on visual examination were obtained. RNA was isolated using Promega ReliaPrep FFPE Total RNA Miniprep System (Wisconsin, USA). cDNA was generated using Omniscript RT-PCR Kit (Qiagen, Germany). Her2 mRNA expression levels from total RNA were determined using TaqMan hydrolysis probe on Bio-Rad QX200 DDPCR platform, California, USA. β-actin was taken as control gene [ Table 1 ].
The DDPCR workflow was done by partitioning the TaqMan (Applied Biosystems, Massachusetts, USA) reaction mix containing sample cDNA into aqueous droplets in oil through the QX100 Droplet Generator. After transfer of droplets to a 96-well PCR plate, a two-step thermocycling protocol followed (95°C for 10 min; 40 cycles of (94°C for 30 s, 55°C for 60 s)) and final step at 98°C for 10 min was carried out in a conventional thermal cycle. Bio-Rad T100; and the PCR plate was then transferred to the QX200 Droplet Reader (a droplet flow cytometer) for automatic reading of samples in all wells. Bio-Rad QX200 reagents and consumables were used for the experiments including droplet generator oil (186-3005), DG8 cartridges (186-4008) and gaskets (186-3009), droplet reader oil (186-3004), and DDPCR supermix for probes (186-3010). About 10 ng of cDNA (3--4 ng/µl concentration) was taken for amplification. Final concentrations of primer probes used for DDPCR were taken as 200 nM each primer, 100 nM each probe in a 20-µl reaction. β-actin was taken as control gene for normalization [ Table 1 ]. The values of Her2 expression were calculated using absolute Her2 (copies/µl)/β-actin (copies/µl) and referred as "DDPCR ratio."
Clinical utility assessment
As already described, "clinical benefit" of a test was defined as proportion of patients labeled conclusively as Her2 positive or negative, as an equivocal result forces the patient to opt for a second-line test. Clinical utility assessment was done in three steps, details of which can be found elsewhere; [19] however, a brief summary is provided below.
First step -determining criteria to define droplet digital polymerase chain reaction categories in the test cohort
Receiver operating characteristic (ROC) curves for DDPCR ratio with FISH outcome as classification variable were analyzed, and subject to values satisfying the criteria corresponding to ≤100 sensitivity and >100% specificity, Her2-"negative," "equivocal," and "positive" patients were assigned a DDPCR score of 1, 2, and 3, respectively. Thus, 1 and 3 comprised a "conclusive DDPCR result category" and "clinically benefitted" from testing.
Second step -simulating data for 1 year to form simulation cohort and defining diagnostic pathways
Data from 2 months were simulated for 1-year subject to following conditions so as to reflect common experience, [22] 25% overall Her2 positivity, [21] and distribution of IHC categories in accordance with results from Bayesian network meta-analysis of unbiased literature reports by Dendukuri et al. [23] Two broad categories of diagnostic pathways with four possibilities were then defined -Two-step pathway comprising (A1) initial IHC followed by FISH for equivocal cases (conventional pathway) and (A2) initial DDPCR followed by FISH for equivocal cases and three-step pathway comprising (B1) initial IHC followed by DDPCR for an equivocal IHC score followed by FISH for an equivocal DDPCR test result and (B2) initial DDPCR followed by IHC for an equivocal DDPCR score followed by FISH for an equivocal IHC test result.
Third step -comparing clinical benefit, incremental cost-effectiveness ratio, and cost benefit for diagnostic pathways in the validation cohort
Clinical benefit of next to last step of two-and three-step pathways was compared. Approach with higher clinical benefit was considered to "dominate" the other. For pathways with initial IHC, incremental cost-effectiveness ratio (ICER) for subsequent FISH or DDPCR followed by FISH was compared from a provider's perspective. Sensitivity analysis was performed to determine probability of three-step pathway incorporating DDPCR as second-line test to remain "cost-effective" over conventional pathway with varying iterations of input parameters. Sensitivity analysis was also performed to compare "cost benefit" of both three-step pathways with varying iterations of input parameters.
Statistical analysis
Quantitative variables were reported as median (interquartile range) and compared using Mann-Whitney U-test, while categorical variables were presented as numbers (proportion). ROC curve analysis was done to assess discriminative ability of DDPCR in identifying Her2-positive cases and define "score categories" as explained previously. Area under the ROC curve (AUC) was reported along with 95% binomial exact confidence interval (CI) and standard error (SE) (MedCalc Statistical Software version 15.8 [MedCalc Software bvba, Ostend, Belgium]). Dendukuri et al. [23] in their meta-analysis determined median 36.1%, 35.5%, 12.2%, and 16.2% patients to be distributed in IHC 0, 1, 2, and 3 categories, respectively. Constraint to overall 25% Her2 positivity and 100% concordance with FISH for "conclusive" IHC categories (categories 0, 1, and 3), straightforward arithmetic logic was used to simulate population for 1 year (assuming 320 patients). For cost-effectiveness analysis, ICER between conventional and three-step pathways was calculated using the following formula:
Foe sensitivity analysis to account for variability in the real world, arithmetic logic was used to derive general equations for ICER and cost benefit (calculated by determining cost difference). Monte Carlo simulation with 100,000 repetitions was used to obtain cumulative distribution plots (IBM SPSS Statistics for Windows v 25.0 [IBM Corp., Armonk, NY, USA]). All costs were calculated relative to cost of one IHC test assumed to be one unit. Cost of one FISH test at our hospital is 3 times the cost of one IHC test, and the same has been reported by others. [23, 24] Two-tailed alpha <0.05 was set as statistically significant beforehand.
Results
Fifty-four patients comprised the study test population, and median age was 52 years. IHC, FISH, and DDPCR were performed for all patients. While none with IHC score of 0 or 1 was FISH positive for Her2, all of the 15 cases with IHC score of 3 were FISH positive. Twenty-six out of 54 cases were assigned IHC score of 2. Thus, 28 (54 − 26) patients benefitted from initial IHC testing (clinical benefit 52% [28/54]) with overall concordance between IHC and FISH being 100% (28/28) for those with IHC score of 0, 1 and 3 (conclusive IHC categories).
Determining criteria to define droplet digital polymerase chain reaction categories in the test cohort
On ROC curve analysis (Appendix 1 for raw data tables), DDPCR score >0.059 had 100% sensitivity while score >1.018 had 100% specificity. Twenty-three cases were assigned that scores intermediate between 0.059 and 1.018. Thus, 31 (54 -23 = 31) patients would have benefitted from DDPCR testing if it was used as a first-line test (clinical benefit: 57%) with concordance between DDPCR and FISH being 100% for those with DDPCR score ≤0.059 and >1.018 with no false-negative or false-positive cases. Thus, DDPCR could discriminate Her2-positive cases with AUC of 0.91, 95% CI 0.80-0.97, SE 0.034, P < 0.0001. Table 2 describes the clinical details including IHC, FISH, and DDPCR distribution of the entire study population. Median DDPCR ratio was significantly lower for Her2-negative cases. If DDPCR would have been used as a second-line test among those with IHC score 2 (n = 26), then only 9 patients would have been assigned an inconclusive category translating to a clinical benefit of 65% ([26 -9]/26) as a second-line test. Table 3 describes the simulated cohort for 1 year (n = 320) and the arithmetic logic behind it. Overall, clinical benefit of IHC as a first-line test was 87.8% (281/320) while that of DDPCR as a first-line test was 59% (189/320). If DDPCR was to be used as a second-line test among those with inconclusive IHC score (n = 39), then its clinical benefit was 74% (29/39) with 10 patients assigned an inconclusive DDPCR score (DDPCR category = 2). If IHC was used as a second-line test among those with inconclusive DDPCR score (n = 131), then its clinical benefit was 92.4% (121/131) with 10 patients assigned an inconclusive IHC score (IHC category = 2). Thus, overall clinical benefit of IHC followed by DDPCR as well as DDPCR followed by IHC was the same (96.9% [310/320]), and two-step pathways were dominated by three step pathways.
Simulating data for 1 year and determining clinical benefit for diagnostic pathways in the simulation cohort

Deriving equations comparing incremental cost-effectiveness ratio and cost benefit for diagnostic pathways in the simulation cohort and sensitivity analysis
Arithmetic logic and equations for ICER and cost-benefit analysis comparing various pathways are described in Table 4 . For sensitivity analysis, Monte Carlo simulation was performed [22] Testing Her2 translation at protein level can also be theoretically problematic as uncommonly, abnormal proteins are degraded in vivo. Further, there may exist patients whose Her2 is not amplified and yet is overexpressed by other mechanisms. Previous data on RNA expression of Her2 are predominantly available for RTPCR, and comparison with different analytical methods such as IHC and FISH has been conflicting. Some authors have reported inadequate concordance and increased number of false negatives, [13, [25] [26] [27] [28] [29] [30] while others reported good concordance. [31, 32] As mentioned earlier, concordance is something that can be artificially manipulated by choosing a particular cutoff, and true value 
For a three-step pathway with DDPCR as second-line test to have superior "cost-effectiveness" over conventional pathway ICER IHC versus IHC followed by DDPCR followed by FISH <ICER IHC versus IHC followed by FISH ⇒xf+xd -xfc 2d < xf ⇒xd< xfc 2d ⇒d < fc 2d ⇒fc 2d −d >0 For a three-step pathway with DDPCR upfront to have superior "cost benefit" over a three-step pathway with IHC upfront -Cost of IHC followed by DDPCR for inconclusive IHC followed by FISH for inconclusive DDPCR > Cost of DDPCR followed by IHC for inconclusive DDPCR followed by FISH for inconclusive IHC ⇒ix Cumulative distribution plot in Figure 1 showed that a three-step pathway with DDPCR as a second-line test had 68% probability to prove more cost-effective than conventional pathway if the cost of DDPCR was 2 times the cost of IHC. Cumulative distribution plot in Figure 2 showed that a three-step pathway with DDPCR upfront could have higher cost benefit than a three-step pathway with immunohistochemistry upfront provided the cost of DDPCR was <0.5 times the cost of immunohistochemistry. Combined interpretation of the two distribution plots implied that if DDPCR cost was ≤0.6 times the cost of IHC, then a three-step pathway with DDPCR upfront would near certainly prove most cost beneficial. If DDPCR cost was >0.6 but ≤2 times the cost of IHC, then a three-step pathway with DDPCR as second-line test had a higher probability to prove most cost beneficial. If DDPCR cost was >2 times the cost of IHC, then conventional pathway had a higher probability to prove most cost-effective.
Discussion
We tried to evaluate clinical utility of an ultra-sensitive PCR (DDPCR) against IHC both as first-line test and among those with IHC score 2 as a reflex second-line test. We chose to study RNA as it has been shown on a cell line study of breast cancer that different methods of of a test is only known by assessing clinical benefit to the patient. Further, certain studies have questioned the use of RTPCR values in equivocal and positive cases for clinical use. [33] Microarray, [34] NanoString, [35] and NGS [36] are newer platforms for gene expression profiling; however, they are expensive and cumbersome, precluding their use outside multigene analysis.
DDPCR is an important methodology in translational cancer research because of its superior sensitivity and accuracy for detection of genomic DNA or RNA expression. [37] The advantages of DDPCR over RTPCR have already been described. The pros and cons of DDPCR versus IHC as a test are explained in IHC. [42] Another study on 102 invasive breast cancer samples by Wang et al. using two digital platforms DDPCR and RainDance for Her2 detection at DNA level (assuming FISH as gold standard) showed a sensitivity and specificity of 82.8% and 97.3% respectively, with a kappa value of 0.833 (P < 0.001) in comparison to IHC. [43] On further testing of 114 equivocal IHC cases, 75% (21/28) Her2-amplified and 95% (82/86) Her2 nonamplified cases were correctly classified as positive and negative by DDPCR, respectively. [43] However, there are very limited data available for detecting Her2 transcript at RNA level, and as explained previously, DNA-based testing for Her2 detection could be unreliable in borderline cases due to differences in detection of Her2 copy numbers by different diagnostic modalities. [18] Furthermore, most of the molecular classifications are based on RNA expression level, and prognostic tests such as Oncotype DX (Genomic Health, USA) and MammaPrint are based on RNA transcript quantification. [44, 45] Hence, there is a strong need of more studies assessing Her2 transcript on this robust platform. We could come across only two previous studies assessing Her2 expression at RNA level using DDPCR. Heredia et al. [46] assessed Her2 in 12 patients both at DNA and RNA levels with data for FISH reported in only 5 cases, while Meehan et al. [18] analyzed 178 cases of breast cancer without reporting FISH data and compared IHC with absolute quantities of mRNA in copies/µl without normalization. Importantly, both studies strongly suggested that mRNA values using DDPCR could be considered as an alternative to IHC. Our study assessed RNA after normalizing with a reference gene and also correlated all cases with FISH findings. In fact, our study went the complete way to assess all cases at DNA, RNA, and protein levels.
Beyond clinical utility, we are the first to evaluate cost-effectiveness of DDPCR in the present diagnostic paradigm for assessing Her2 status in breast cancer. Our results showed that introducing DDPCR as a second-line test in the conventional pathway could improve its cost-effectiveness if the cost of one DDPCR test was ≤2 times the cost of one IHC test. However, in reality, the actual cost of one DDPCR test is likely to be lower than that of one IHC test. In terms of input costs, the quotation of a new DDPCR machine offered to our hospital was 60% of the cost of a new IHC machine. Both IHC and DDPCR require one trained person with 4-6 working h for each run. Further, each run of DDPCR is around 3$ per reaction, [47, 48] IHC around 100$-150$, and FISH being double to triple of IHC. [49] Importantly, if cost of one DDPCR test was ≤60% of one IHC test, then a three-step pathway with DDPCR upfront had 
t h r e e -s t e p p a t h w a y w i t h d r o p l e t d i g i t a l p o l y m e r a s e chain reaction upfront versus a t h r e e -s t e p p a t h w a y w i t h immunohistochemistry upfront, with varying fixed costs of droplet digital polymerase chain reaction. A three-step pathway with DDPCR upfront could have higher cost benefit than a three-step pathway w i t h i m m u n o h i s t o c h e m i s t r y upfront provided the cost of
Conclusion
We performed a comprehensive audit of clinical utility of DDPCR in ascertaining presence or absence of Her2 expression at RNA level in FFPE samples of breast cancer and describe its clinical protocol and cutoffs. Incorporating DDPCR in the current clinical paradigm of assessing Her2 expression in breast cancer has the potential to improve its cost-effectiveness and benefit.
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There are no conflicts of interest. The concept of pathologic complete response (pCR) has been an enigmatic one, often at the center of much debate and controversy. While most researchers would agree that the absence of residual invasive carcinoma in the breast and axilla is imperative in defining pCR, the impact of residual in situ tumor is still debated. The current AJCC 8 th Edition defines pCR as the absence of any residual invasive carcinoma in the breast/axilla/lymph vessels. The presence of in situ tumor in the absence of invasive carcinoma still constitutes a pCR. [1] From the early studies onward, pCR showed great promise in its ability to predict outcomes after chemotherapy. This association was strongest in aggressive biology tumors, such as triple-negative and HER2-positive cancers. [2] Researchers surmised that pCR could potentially be a surrogate marker for survival. Based on its ability to improve pCR rates, [3] pertuzumab was the first drug to receive accelerated approval from the Food and Drug Administration in 2013. The corresponding adjuvant trial (APHINITY) demonstrated only a marginal improvement in disease-free survival (94.1% vs. 93.2%, P = 0.045) in its early analysis, and further maturing of data is awaited. Along similar lines, addition of lapatinib improved pCR rates significantly; however, in the adjuvant setting, it failed to impact survival outcomes. [4, 5] The CTNeoBC meta-analysis [6] funded by the US-FDA confirmed the prognostic value of pCR, especially in aggressive tumor subtypes; however, it could not validate pCR as a surrogate endpoint for survival.
Criterion values and coordinates of the receiver operating characteristic curves
Following this, pCR continued to simmer for a while and found its clinical application in its ability to prognosticate aggressive subtypes. However, the recent turn of events, specifically the CREATE-X [7] and KATHERINE [8] trials, has demonstrated, a hitherto unexplored, predictive capability of pCR. The CREATE-X study suggested a survival benefit with the addition of capecitabine, in women with triple-negative breast cancer, with residual disease post-neoadjuvant chemotherapy (NACT). Likewise, the early analysis of KATHERINE points toward a benefit in invasive disease-free survival with Trastuzumab emtansine over trastuzumab, in HER2-positive breast cancers with residual disease post-NACT. In both these studies, pCR, or more specifically, the lack of it, was used as a marker to tailor adjuvant therapy, with improved outcomes.
